Resonance Health Ltd (AU:RHT)
ASX:RHT
Want to see AU:RHT full AI Analyst Report?
RHT Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.06
Previous CloseN/A
Volume166.47K
Average Volume (3M)274.25K
Market Cap
AU$20.52M
Enterprise ValueAU$23.02M
Total Cash (Recent Filing)AU$2.69M
Total Debt (Recent Filing)AU$5.20M
Price to Earnings (P/E)4.0
Beta1.59
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume456,299
30 Day Avg. Volume274,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.89
Price to Sales (P/S)1.60
P/FCF Ratio22.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring & Usage-based Revenue ModelA mix of subscription/licensing and per-scan fees creates diversified, recurring cash streams and aligns revenue with customer usage. This model supports predictable revenue growth, higher customer retention through embedded workflows, and scalable unit economics as scan volumes and clinical-trial work increase.
Modest But Positive Revenue GrowthConsistent revenue growth, even if modest, indicates product-market fit and ongoing adoption of imaging software and services. Sustainable top-line expansion enables reinvestment in R&D and regulatory/commercial efforts, improving long-term competitiveness if margins can be addressed.
Conservative Leverage And Capital StructureModerate leverage and a solid equity ratio provide financial flexibility and lower interest burden, helping the company withstand clinical and reimbursement cycles. This capital structure supports continued investment in product development and partnership execution without acute solvency risk.
Bears Say
Negative ProfitabilityPersistent negative EBIT and net margins erode the firm's ability to self-fund growth and may force reliance on external capital. Continued unprofitability reduces return on invested capital, constrains strategic flexibility, and heightens risk if revenue growth slows or competitive pressure increases.
Steep Decline In Free Cash FlowA two‑thirds drop in free cash flow materially weakens internal funding for operations, R&D, and commercialization. Lower FCF raises refinancing and liquidity risk, limits ability to invest in scale or partnerships, and could force dilutive financing or cutbacks if the trend persists.
Very Small Team Limits ScalingA headcount of 18 constrains capacity for sales, regulatory work, product development, and global customer support. Limited human capital increases execution risk, slows enterprise adoption and clinical-trial throughput, and makes rapid scaling or multi-market expansion more challenging.
Resonance Health Ltd News
RHT FAQ
What was Resonance Health Ltd’s price range in the past 12 months?
Resonance Health Ltd lowest share price was AU$0.03 and its highest was AU$0.06 in the past 12 months.
What is Resonance Health Ltd’s market cap?
Resonance Health Ltd’s market cap is AU$20.52M.
When is Resonance Health Ltd’s upcoming earnings report date?
Resonance Health Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 102 days.
How were Resonance Health Ltd’s earnings last quarter?
Resonance Health Ltd released its earnings results on Feb 26, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Resonance Health Ltd overvalued?
According to Wall Street analysts Resonance Health Ltd’s price is currently Overvalued.
Does Resonance Health Ltd pay dividends?
Resonance Health Ltd does not currently pay dividends.
What is Resonance Health Ltd’s EPS estimate?
Resonance Health Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Resonance Health Ltd have?
Resonance Health Ltd has 477,120,240 shares outstanding.
What happened to Resonance Health Ltd’s price movement after its last earnings report?
Resonance Health Ltd reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Resonance Health Ltd?
Currently, no hedge funds are holding shares in AU:RHT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Resonance Health Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RHT Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$106.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.14%
12-Months-Change
Fundamentals
Return on Equity
7.57%
Trailing 12-Months
Asset Growth
0.14%
Trailing 12-Months
Company Description
Resonance Health Ltd
Resonance Health Limited, a healthcare technology and services company, designs, develops, and manufactures software-as-medical devices in the Asia Pacific, North America, South America, Europe, the Middle East, and Africa. It offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-assisted device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also offers quantitative imaging measurements and CRO, such as quality-assured image analysis, imaging charter development, project and data management, issue resolution, site tracker and clinical trial progress report, and coordination of data flow services; biomarkers, blood, urine, and protein analytes, as well as RNA, DNA, and genotyping services; and protocol development, assessment of subject inclusion or exclusion, decisions on dose modifications, and evaluating the safety profile of a new therapy, as well as supporting primary and secondary end-points demonstrating drug efficacy services for multinational and multicenter clinical trials; and phantoms for the calibration of MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
Technical Analysis
Singular Health Group Ltd
―
ImExHS Limited
―
Emyria Ltd
―
HitIQ Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---